A Novel Drug Delivery System of Oral Curcumin Markedly Improves Efficacy of Treatment for Heart Failure after Myocardial Infarction in Rats

• Sunagawa Yoichi

  Human Health Sciences, Graduate School of Medicine, Kyoto University Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka

• Wada Hiromichi

  Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization

• Suzuki Hidetoshi

  Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka

• Sasaki Hiroki

  Theravalues Corporation

• Imaizumi Atsushi

  Theravalues Corporation

• Fukuda Hiroyuki

  Theravalues Corporation

• Hashimoto Tadashi

  Theravalues Corporation

• Katanasaka Yasufumi

  Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka

• Shimatsu Akira

  Clinical Research Institute, Kyoto Medical Center, National Hospital Organization

• Kimura Takeshi

  Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University

• Kakeya Hideaki

  Department of System Chemotherapy and Molecular Sciences, Division of Bioinformatics and Chemical Genomics, Graduate School of Pharmaceutical Sciences, Kyoto University

• Fujita Masatoshi

  Human Health Sciences, Graduate School of Medicine, Kyoto University

• Hasegawa Koji

  Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization

• Morimoto Tatsuya

  Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka

Bibliographic Information

Other Title

• Application of Curcumin to Heart Failure Therapy by Targeting Transcriptional Pathway in Cardiomyocytes

Abstract

Curcumin is an inhibitor of p300 histone acetyltransferase activity, which is associated with the deterioration of heart failure. We reported that native curcumin, at a dosage of 50 mg/kg, prevented deterioration of the systolic function in rat models of heart failure. To achieve more efficient oral pharmacological therapy against heart failure by curcumin, we have developed a novel drug delivery system (DDS) which markedly increases plasma curcumin levels. At the dosage of 0.5 mg/kg, DDS curcumin but not native curcumin restored left ventricular fractional shortening in post-myocardial infarction rats. Thus, our DDS strategy will be applicable to the clinical setting in humans.

Journal

• Biological and Pharmaceutical Bulletin

  Biological and Pharmaceutical Bulletin 35 (2), 139-144, 2012

  The Pharmaceutical Society of Japan

Keywords

• curcumin
• drug delivery system
• heart failure

Details

• CRID: 1390001204631883520
• NII Article ID: 130001872286
• NII Article ID: 130003361361
• NII Book ID: AA10885497
• DOI: 10.1248/bpb.35.139
• DOI: 10.1248/bpb.b212022
• COI: 1:STN:280:DC%2BC387pt1yntA%3D%3D
• COI: 1:STN:280:DC%2BC3s3otFaitg%3D%3D
• ISSN: 13475215
• ISSN: 09186158
• NDL BIB ID: 023408351
• NDL BIB ID: 024173317
• PubMed: 22293342
• PubMed: 23302632
• Web Site: http://id.ndl.go.jp/bib/023408351
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I023408351
• Web Site: http://id.ndl.go.jp/bib/024173317
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I024173317
• Web Site: http://www.jstage.jst.go.jp/article/bpb/35/2/35_2_139/_pdf
• Web Site: https://www.jstage.jst.go.jp/article/bpb/36/1/36_b212022/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2012244716
• Text Lang: en
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed